Randall Mark Zusman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antihypertensive Agents | 19 | 2008 | 2061 | 0.770 |
Why?
|
| Hypertension | 33 | 2018 | 8594 | 0.760 |
Why?
|
| Erectile Dysfunction | 6 | 2000 | 452 | 0.670 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 4 | 1999 | 56 | 0.660 |
Why?
|
| Phosphodiesterase Inhibitors | 4 | 2000 | 214 | 0.630 |
Why?
|
| Piperazines | 7 | 2005 | 2525 | 0.500 |
Why?
|
| Blood Pressure | 32 | 2018 | 8525 | 0.490 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 11 | 2003 | 1523 | 0.440 |
Why?
|
| Relaxation Therapy | 2 | 2018 | 179 | 0.420 |
Why?
|
| Arteriosclerosis | 3 | 2000 | 1064 | 0.380 |
Why?
|
| Propranolol | 5 | 2011 | 489 | 0.350 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2000 | 189 | 0.320 |
Why?
|
| Platelet Aggregation Inhibitors | 6 | 2000 | 3201 | 0.320 |
Why?
|
| Heart Rate | 12 | 2012 | 4179 | 0.300 |
Why?
|
| Nifedipine | 4 | 1999 | 221 | 0.290 |
Why?
|
| Doxazosin | 2 | 2004 | 18 | 0.280 |
Why?
|
| Ticlopidine | 3 | 2000 | 895 | 0.270 |
Why?
|
| Acupuncture | 1 | 2006 | 90 | 0.270 |
Why?
|
| Angina Pectoris | 6 | 2000 | 969 | 0.260 |
Why?
|
| Coronary Disease | 4 | 2000 | 5990 | 0.250 |
Why?
|
| Bepridil | 4 | 1993 | 12 | 0.240 |
Why?
|
| Critical Pathways | 3 | 2009 | 475 | 0.230 |
Why?
|
| Prostaglandins | 7 | 1987 | 398 | 0.230 |
Why?
|
| Proline | 3 | 1992 | 457 | 0.220 |
Why?
|
| Sulfones | 7 | 2005 | 447 | 0.220 |
Why?
|
| Renin | 10 | 1994 | 635 | 0.210 |
Why?
|
| Purines | 7 | 2005 | 605 | 0.210 |
Why?
|
| Heart | 8 | 2012 | 4393 | 0.200 |
Why?
|
| Diltiazem | 2 | 1992 | 131 | 0.170 |
Why?
|
| Prostatic Hyperplasia | 1 | 2004 | 530 | 0.170 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2000 | 174 | 0.170 |
Why?
|
| Acupuncture Therapy | 1 | 2004 | 480 | 0.170 |
Why?
|
| Ventricular Function, Left | 7 | 1999 | 3880 | 0.160 |
Why?
|
| Captopril | 4 | 1988 | 265 | 0.160 |
Why?
|
| Cardiology | 2 | 2000 | 1723 | 0.160 |
Why?
|
| Drug Interactions | 6 | 2000 | 1428 | 0.160 |
Why?
|
| Activities of Daily Living | 1 | 2008 | 2417 | 0.160 |
Why?
|
| Enzyme Inhibitors | 2 | 1999 | 3726 | 0.150 |
Why?
|
| Nitroglycerin | 5 | 1999 | 329 | 0.150 |
Why?
|
| Angiotensin II | 6 | 1994 | 849 | 0.130 |
Why?
|
| Life Style | 1 | 2008 | 3896 | 0.130 |
Why?
|
| Double-Blind Method | 13 | 2008 | 12427 | 0.130 |
Why?
|
| Oligopeptides | 4 | 1994 | 1187 | 0.120 |
Why?
|
| Vasodilator Agents | 4 | 2005 | 978 | 0.120 |
Why?
|
| Vasodilation | 1 | 1999 | 962 | 0.120 |
Why?
|
| Cardiovascular Diseases | 6 | 2009 | 15757 | 0.120 |
Why?
|
| Clinical Trials as Topic | 14 | 2004 | 8056 | 0.120 |
Why?
|
| Prostaglandins E | 4 | 1984 | 169 | 0.120 |
Why?
|
| Vascular Resistance | 6 | 1993 | 933 | 0.110 |
Why?
|
| Drug Therapy, Combination | 9 | 2006 | 6498 | 0.110 |
Why?
|
| Nitric Oxide | 2 | 1999 | 2141 | 0.110 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 1999 | 1031 | 0.110 |
Why?
|
| Epoprostenol | 3 | 1985 | 248 | 0.100 |
Why?
|
| Stress, Psychological | 1 | 2008 | 4446 | 0.100 |
Why?
|
| Exercise Test | 6 | 2012 | 2128 | 0.100 |
Why?
|
| Atenolol | 1 | 1992 | 99 | 0.100 |
Why?
|
| Hemodynamics | 4 | 1993 | 4174 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2011 | 1259 | 0.100 |
Why?
|
| Dextroamphetamine | 1 | 2012 | 134 | 0.100 |
Why?
|
| Patient Selection | 1 | 2004 | 4283 | 0.100 |
Why?
|
| Cardiovascular System | 1 | 1999 | 850 | 0.090 |
Why?
|
| Drive | 1 | 2011 | 34 | 0.090 |
Why?
|
| Central Nervous System Stimulants | 2 | 2012 | 1174 | 0.090 |
Why?
|
| Sexual Behavior | 1 | 2000 | 2086 | 0.090 |
Why?
|
| Calcium Channel Blockers | 4 | 1989 | 694 | 0.090 |
Why?
|
| Dipeptides | 1 | 1992 | 409 | 0.090 |
Why?
|
| Diuretics | 3 | 1988 | 613 | 0.090 |
Why?
|
| Imagination | 1 | 2011 | 226 | 0.080 |
Why?
|
| Renin-Angiotensin System | 4 | 1992 | 738 | 0.080 |
Why?
|
| Radionuclide Angiography | 4 | 1993 | 23 | 0.080 |
Why?
|
| Coitus | 2 | 2000 | 131 | 0.080 |
Why?
|
| Myocardial Infarction | 2 | 2000 | 11891 | 0.080 |
Why?
|
| Kidney Medulla | 3 | 1984 | 169 | 0.080 |
Why?
|
| Humans | 66 | 2018 | 760621 | 0.080 |
Why?
|
| Bradykinin | 3 | 1987 | 208 | 0.080 |
Why?
|
| Research Design | 1 | 2004 | 6180 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 6 | 2009 | 7475 | 0.070 |
Why?
|
| Arachidonic Acids | 1 | 1987 | 294 | 0.070 |
Why?
|
| Diastole | 4 | 1993 | 788 | 0.070 |
Why?
|
| Coronary Circulation | 2 | 2005 | 1577 | 0.070 |
Why?
|
| Male | 41 | 2018 | 359744 | 0.070 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 1992 | 854 | 0.070 |
Why?
|
| Pyrrolidines | 2 | 1985 | 340 | 0.070 |
Why?
|
| Cardiac Output | 3 | 1993 | 838 | 0.060 |
Why?
|
| Brain Ischemia | 1 | 1999 | 3127 | 0.060 |
Why?
|
| Amphetamines | 1 | 2006 | 143 | 0.060 |
Why?
|
| Myocardial Contraction | 1 | 1989 | 1516 | 0.060 |
Why?
|
| Arginine Vasopressin | 1 | 1984 | 125 | 0.060 |
Why?
|
| Random Allocation | 6 | 1988 | 2394 | 0.060 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2012 | 3701 | 0.060 |
Why?
|
| Adult | 30 | 2018 | 219994 | 0.060 |
Why?
|
| Personal Satisfaction | 1 | 2008 | 643 | 0.050 |
Why?
|
| Systole | 4 | 1999 | 947 | 0.050 |
Why?
|
| Butanones | 1 | 2003 | 28 | 0.050 |
Why?
|
| Middle Aged | 27 | 2018 | 220352 | 0.050 |
Why?
|
| Fosinopril | 2 | 1992 | 7 | 0.050 |
Why?
|
| Myocardial Ischemia | 2 | 2005 | 2164 | 0.050 |
Why?
|
| Ibuprofen | 1 | 2003 | 229 | 0.050 |
Why?
|
| Uremia | 1 | 1981 | 201 | 0.040 |
Why?
|
| Prazosin | 1 | 2000 | 95 | 0.040 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 1999 | 60 | 0.040 |
Why?
|
| United States | 8 | 2009 | 72461 | 0.040 |
Why?
|
| Reference Values | 3 | 1999 | 4925 | 0.040 |
Why?
|
| Aged | 15 | 2018 | 169152 | 0.040 |
Why?
|
| Delayed-Action Preparations | 3 | 2006 | 961 | 0.040 |
Why?
|
| Blood Platelets | 2 | 2000 | 2520 | 0.040 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 1999 | 148 | 0.040 |
Why?
|
| Algorithms | 3 | 2009 | 13981 | 0.040 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2011 | 4555 | 0.040 |
Why?
|
| Biological Availability | 1 | 1999 | 395 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 1999 | 361 | 0.040 |
Why?
|
| Female | 29 | 2018 | 391270 | 0.040 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 1999 | 186 | 0.040 |
Why?
|
| Relaxation | 1 | 2018 | 51 | 0.040 |
Why?
|
| Stents | 2 | 2000 | 3314 | 0.040 |
Why?
|
| Aldosterone | 4 | 1994 | 868 | 0.040 |
Why?
|
| Stroke | 1 | 2000 | 9962 | 0.040 |
Why?
|
| Risk Factors | 6 | 2000 | 74359 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2008 | 2628 | 0.040 |
Why?
|
| Receptors, Angiotensin | 3 | 1984 | 141 | 0.040 |
Why?
|
| Risk | 2 | 1999 | 9631 | 0.030 |
Why?
|
| Angina, Unstable | 2 | 1993 | 926 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2018 | 54303 | 0.030 |
Why?
|
| Safety | 1 | 2000 | 1148 | 0.030 |
Why?
|
| Calcium | 2 | 1989 | 5725 | 0.030 |
Why?
|
| Sodium | 4 | 1983 | 1594 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1999 | 1754 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2000 | 782 | 0.030 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 1 | 1974 | 29 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 1991 | 4371 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2005 | 3112 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 15840 | 0.030 |
Why?
|
| Heart Diseases | 2 | 1999 | 2809 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2004 | 8555 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1994 | 660 | 0.030 |
Why?
|
| Heart Function Tests | 1 | 1993 | 319 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2003 | 1977 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 2282 | 0.030 |
Why?
|
| Lisinopril | 1 | 1992 | 55 | 0.030 |
Why?
|
| Urine | 1 | 1994 | 363 | 0.030 |
Why?
|
| Heart Valve Diseases | 1 | 2000 | 1047 | 0.030 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 1993 | 227 | 0.030 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2000 | 1572 | 0.020 |
Why?
|
| Chlorthalidone | 1 | 1991 | 21 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 1981 | 1801 | 0.020 |
Why?
|
| Administration, Oral | 1 | 1999 | 4035 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2009 | 12293 | 0.020 |
Why?
|
| Supination | 1 | 1991 | 68 | 0.020 |
Why?
|
| Fibrinolytic Agents | 1 | 1981 | 2167 | 0.020 |
Why?
|
| Infusion Pumps | 1 | 1991 | 163 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 1999 | 1677 | 0.020 |
Why?
|
| Stroke Volume | 3 | 1993 | 5523 | 0.020 |
Why?
|
| Comorbidity | 2 | 2006 | 10551 | 0.020 |
Why?
|
| Sodium Chloride | 2 | 1987 | 591 | 0.020 |
Why?
|
| Kinins | 2 | 1979 | 14 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2008 | 65017 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 1741 | 0.020 |
Why?
|
| Galvanic Skin Response | 1 | 2011 | 348 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 2 | 1981 | 2471 | 0.020 |
Why?
|
| Leg | 1 | 1993 | 1090 | 0.020 |
Why?
|
| Liver Diseases | 1 | 1977 | 1302 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2011 | 6015 | 0.020 |
Why?
|
| Platelet Aggregation | 2 | 1981 | 805 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 1999 | 3696 | 0.020 |
Why?
|
| Aspirin | 1 | 1999 | 3364 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 1989 | 593 | 0.020 |
Why?
|
| Culture Techniques | 2 | 1984 | 530 | 0.020 |
Why?
|
| Homeostasis | 2 | 1994 | 3306 | 0.020 |
Why?
|
| Angiotensinogen | 2 | 1983 | 161 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 1987 | 433 | 0.020 |
Why?
|
| Electromyography | 1 | 2011 | 1388 | 0.020 |
Why?
|
| Time Factors | 4 | 1999 | 40165 | 0.020 |
Why?
|
| Electrocardiography | 4 | 2006 | 6414 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1989 | 791 | 0.020 |
Why?
|
| Enalapril | 1 | 1987 | 313 | 0.020 |
Why?
|
| Psychotropic Drugs | 1 | 1991 | 883 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 1987 | 713 | 0.020 |
Why?
|
| Norepinephrine | 1 | 1987 | 900 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1987 | 1628 | 0.020 |
Why?
|
| Ischemia | 1 | 1993 | 1893 | 0.020 |
Why?
|
| Trifluoperazine | 1 | 1984 | 37 | 0.010 |
Why?
|
| Psychophysiologic Disorders | 1 | 1986 | 221 | 0.010 |
Why?
|
| Calcimycin | 1 | 1984 | 213 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1984 | 306 | 0.010 |
Why?
|
| Physical Exertion | 1 | 1987 | 662 | 0.010 |
Why?
|
| Anger | 1 | 1986 | 401 | 0.010 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 820 | 0.010 |
Why?
|
| Verapamil | 1 | 1984 | 242 | 0.010 |
Why?
|
| Lipoproteins | 1 | 1988 | 882 | 0.010 |
Why?
|
| Heart Failure | 2 | 2000 | 11847 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 1988 | 1677 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1999 | 10344 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 1989 | 1296 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2006 | 640 | 0.010 |
Why?
|
| Rabbits | 3 | 1984 | 4773 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 9411 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1987 | 3084 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1981 | 399 | 0.010 |
Why?
|
| Dinoprostone | 1 | 1984 | 598 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1987 | 1190 | 0.010 |
Why?
|
| Psychometrics | 1 | 2011 | 3051 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1985 | 1975 | 0.010 |
Why?
|
| World Health Organization | 1 | 1986 | 1312 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 1987 | 1817 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2000 | 58995 | 0.010 |
Why?
|
| Receptors, Cell Surface | 2 | 1980 | 2825 | 0.010 |
Why?
|
| Teprotide | 1 | 1979 | 25 | 0.010 |
Why?
|
| Blood Coagulation | 2 | 1987 | 1157 | 0.010 |
Why?
|
| Echocardiography | 1 | 2012 | 4981 | 0.010 |
Why?
|
| Bartter Syndrome | 1 | 1979 | 23 | 0.010 |
Why?
|
| Cholesterol | 1 | 1988 | 2924 | 0.010 |
Why?
|
| Triglycerides | 1 | 1987 | 2476 | 0.010 |
Why?
|
| Medication Adherence | 1 | 2011 | 2165 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2000 | 24123 | 0.010 |
Why?
|
| Posture | 1 | 1983 | 953 | 0.010 |
Why?
|
| Body Temperature | 1 | 1981 | 777 | 0.010 |
Why?
|
| Patient Compliance | 1 | 1988 | 2688 | 0.010 |
Why?
|
| Prostaglandins A | 1 | 1977 | 13 | 0.010 |
Why?
|
| Prostaglandins F | 1 | 1977 | 80 | 0.010 |
Why?
|
| Prostaglandins, Synthetic | 1 | 1977 | 24 | 0.010 |
Why?
|
| Natriuresis | 1 | 1977 | 105 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 1977 | 182 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 1974 | 4312 | 0.010 |
Why?
|
| Diuresis | 1 | 1977 | 107 | 0.010 |
Why?
|
| Quality of Life | 2 | 1989 | 13308 | 0.010 |
Why?
|
| Potassium | 3 | 1979 | 1313 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 6238 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 1989 | 3811 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1974 | 6315 | 0.010 |
Why?
|
| Accidents, Traffic | 1 | 2002 | 814 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 1999 | 1121 | 0.010 |
Why?
|
| Arousal | 1 | 2002 | 1157 | 0.010 |
Why?
|
| Hyperaldosteronism | 1 | 1979 | 244 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1999 | 1377 | 0.010 |
Why?
|
| Renal Artery | 1 | 1977 | 370 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2012 | 22053 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 1067 | 0.010 |
Why?
|
| Adolescent | 3 | 2011 | 87810 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 4899 | 0.010 |
Why?
|
| Heparin | 1 | 1981 | 1652 | 0.010 |
Why?
|
| Steroids | 1 | 1979 | 928 | 0.010 |
Why?
|
| Age Factors | 2 | 2006 | 18416 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2003 | 1999 | 0.010 |
Why?
|
| Foreign-Body Migration | 1 | 1993 | 218 | 0.010 |
Why?
|
| Catheterization | 1 | 1977 | 1432 | 0.010 |
Why?
|
| Equipment Failure | 1 | 1993 | 577 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 1989 | 5325 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 1973 | 681 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 1993 | 625 | 0.010 |
Why?
|
| Syndrome | 1 | 1977 | 3280 | 0.010 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1993 | 560 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 1993 | 1098 | 0.010 |
Why?
|
| Body Weight | 2 | 1987 | 4611 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 10827 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 6465 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 39261 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1981 | 3600 | 0.000 |
Why?
|
| Acute Kidney Injury | 1 | 1981 | 1941 | 0.000 |
Why?
|
| Animals | 6 | 1987 | 167963 | 0.000 |
Why?
|
| Nephrectomy | 1 | 1974 | 1016 | 0.000 |
Why?
|
| Pacemaker, Artificial | 1 | 1993 | 815 | 0.000 |
Why?
|
| Thallium | 1 | 1987 | 100 | 0.000 |
Why?
|
| Retrospective Studies | 2 | 2011 | 80372 | 0.000 |
Why?
|
| Hostility | 1 | 1987 | 183 | 0.000 |
Why?
|
| Mental Disorders | 1 | 2006 | 6796 | 0.000 |
Why?
|
| Vagotomy | 1 | 1985 | 83 | 0.000 |
Why?
|
| Radioisotopes | 1 | 1987 | 495 | 0.000 |
Why?
|
| Pressoreceptors | 1 | 1985 | 100 | 0.000 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1985 | 221 | 0.000 |
Why?
|
| Sympathetic Nervous System | 1 | 1987 | 520 | 0.000 |
Why?
|
| Denervation | 1 | 1985 | 277 | 0.000 |
Why?
|
| Pepstatins | 1 | 1983 | 10 | 0.000 |
Why?
|
| Young Adult | 1 | 2011 | 58741 | 0.000 |
Why?
|
| Coronary Artery Bypass | 1 | 1993 | 2272 | 0.000 |
Why?
|
| Haplorhini | 1 | 1983 | 529 | 0.000 |
Why?
|
| Placebos | 1 | 1987 | 1668 | 0.000 |
Why?
|
| Emergency Service, Hospital | 1 | 2002 | 7818 | 0.000 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 1983 | 311 | 0.000 |
Why?
|
| Postoperative Complications | 2 | 1993 | 15697 | 0.000 |
Why?
|
| Carotid Arteries | 1 | 1985 | 951 | 0.000 |
Why?
|
| Phenylmethylsulfonyl Fluoride | 1 | 1980 | 6 | 0.000 |
Why?
|
| Dithiothreitol | 1 | 1980 | 95 | 0.000 |
Why?
|
| Dogs | 1 | 1985 | 3841 | 0.000 |
Why?
|
| Organ Size | 1 | 1985 | 2254 | 0.000 |
Why?
|
| Protease Inhibitors | 1 | 1983 | 755 | 0.000 |
Why?
|
| Prekallikrein | 1 | 1979 | 11 | 0.000 |
Why?
|
| Monitoring, Physiologic | 1 | 1987 | 1784 | 0.000 |
Why?
|
| Fludrocortisone | 1 | 1979 | 24 | 0.000 |
Why?
|
| Spleen | 1 | 1985 | 2298 | 0.000 |
Why?
|
| Aorta | 1 | 1985 | 2039 | 0.000 |
Why?
|
| Kallikreins | 1 | 1979 | 231 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1987 | 6538 | 0.000 |
Why?
|
| Social Class | 1 | 1986 | 2005 | 0.000 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1979 | 618 | 0.000 |
Why?
|
| Iodine Radioisotopes | 1 | 1980 | 1032 | 0.000 |
Why?
|
| Antibodies | 1 | 1983 | 2421 | 0.000 |
Why?
|
| Coronary Angiography | 1 | 1987 | 4563 | 0.000 |
Why?
|
| Diet | 1 | 1973 | 8010 | 0.000 |
Why?
|
| Sex Factors | 1 | 1986 | 10547 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1983 | 13451 | 0.000 |
Why?
|
| Binding Sites | 1 | 1980 | 6048 | 0.000 |
Why?
|
| Depression | 1 | 1987 | 8044 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1983 | 9185 | 0.000 |
Why?
|
| Obesity | 1 | 1986 | 12922 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1979 | 18957 | 0.000 |
Why?
|
| Child | 1 | 1979 | 79806 | 0.000 |
Why?
|